Pillar 1 - FTO (new thread), page-1720

Hey @RaceOncology,

Just a quick query - I thought I had a handle on this but a gap in my understanding has popped up when I was challenged on FTO inhibition today.

Given the universal nature of m6a modification within the mRNA epitranscriptome realm:

1. How is Zantrene delivered such that is only targets cancerous cells and does not impact FTO levels/normal m6a demethylation levels in adjacent tissue/cells

2. if Zantrene is unable to be exceptionally accurately delivered to ONLY target cells, what impact on adjacent healthy cell function could be expected if Zantrene downregulates FTO in this tissue?

@Mason14 has posted a paper showing that human foetal development was still achievable with no FTO levels whatsoever due to a genetic defect - so curious to see what we’d expect to see if we deprived healthy adjacent tissue due to collateral impact.

Thanks!